{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-032259","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2021-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.477568+00:00","generated_at":"2026-06-27T22:52:02.881677+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Bone Biologics enters revised employment agreement with CFO, base salary $200K","bullets":["Employment agreement effective Jan 3, 2022; at-will; base salary $200,000.","Annual target bonus of 25% of base salary, subject to board-set objectives.","Stock option grant of 25,000 shares with 2-year maturity at market price.","CFO Deina H. Walsh has served since Nov 2014; new agreement updates terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-032259","json":"https://secwatch.observer/filing/0001493152-21-032259.json","markdown":"https://secwatch.observer/filing/0001493152-21-032259.md","text":"https://secwatch.observer/filing/0001493152-21-032259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315221032259/0001493152-21-032259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315221032259/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T22:52:02.881677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}